Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT01978405

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01978405
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01978405. Randomized; single masking; primary purpose prevention. Start 2013-11 (registry gives no type); primary completion 2014-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes
Condition
The Changes of Plasma Creatinine
Condition
The Changes of Plasma Free Radicals
Condition
The Changes of Endothelium-dependent Arterial Dilation
Intervention (Drug)
Alpha lipoic acid
Lead sponsor
Xiang Guang-da (class: other)

Record details

Record id
cardio:ct-nct01978405
Content hash
ed0172114b2519eb9511d8b4a44262ceeb596a455128b24f79ed759c8927c4c9